《Table 1.Study characteristics for the included studies.》

  提示：宽带有限、当前游客访问压缩模式

本系列图表出处文件名：随高清版一同展现

《华蟾素注射液治疗中晚期原发性肝癌的统评价和Meta分析（英文）》

1. 获取 高清版本忘记账户？点击这里登录

1. 下载图表忘记账户？点击这里登录

A total of 233 studies were identified through electronic searches of CENTRAL in The Cochrane Library（n=1），Pub Med（n=65），EMBASE（n=24），and four Chinese Databases（CBM，VIP，CNKI，Wangfang）（n=1089） .Figure 1 demonstrates the details of the study selection and search process.A total of 732 publications were initially retrieved，from which 24 RCTs concerning cinobufacini injection in liver cancer were identified.Moreover，13 trials were subsequently excluded for the following reasons:1) one was excluded as it was a meta-analysis[21]；2) three studies evaluated the role of the cinobufacini tablet，not the injection；3) four studies reported incomplete and incomprehensive outcomes and did not meet the inclusion criteria；and 4) five studies were not randomly assigned.Overall，11 RCTs consisting of 728 patients，including 370 patients who were treated with cinobufacini injection met the inclusion criteria and were analyzed in this study[22–32].Table 1 shows the study characteristics for the included trials.Table 2 displays the methodological quality of these trials.Figure 2 demonstrates the low potential for publication bias.